Bork J, Chinnock R, Ogata K, Baum M
Department of Pediatrics, Loma Linda University Medical Center, CA 92354.
J Heart Lung Transplant. 1993 Nov-Dec;12(6 Pt 2):S199-202.
Previously we reported that the rate of mild to moderate infections and upper respiratory infections in infants who undergo transplantation under 1 year of age was the same as that of the general population. Despite this, serious infections continue to be one of the major complications in the first 3 to 4 months after heart transplantation. Among newborns and infants at Loma Linda University Medical Center, there have been 35 deaths from various causes: six (17%) were the result of infectious causes, three were in the early perioperative period, and three were late complications. There were no deaths caused directly by cytomegalovirus. From 1989 to 1992, 128 under 1 year of age underwent transplantation. Of these, 65 had at least one episode of serious infection ranging from bacterial meningitis to viral pneumonia. Of these infants, 19 had cytomegalovirus infections, with the vast majority having symptoms in the first 2 to 3 months after transplantation. Eight infants had Pneumocystis pneumonia and were treated successfully. The risk of cytomegalovirus is highest in the first 4 to 8 weeks after transplantation and in a seronegative recipient who has received an organ from a seropositive donor. Currently, our protocol to reduce the likelihood of active disease includes the use of intravenous immunoglobulin immediately after transplantation and during rejection episodes that are treated with aggressive immunosuppression and the use of oral acyclovir for the first 3 months after transplantation. If active disease develops, ganciclovir is initiated.(ABSTRACT TRUNCATED AT 250 WORDS)
此前我们报道,1岁以下接受移植的婴儿中轻度至中度感染及上呼吸道感染的发生率与普通人群相同。尽管如此,严重感染仍是心脏移植后最初3至4个月的主要并发症之一。在洛马林达大学医学中心的新生儿和婴儿中,有35例因各种原因死亡:6例(17%)死于感染性原因,3例死于围手术期早期,3例死于晚期并发症。没有直接由巨细胞病毒引起的死亡病例。1989年至1992年,128名1岁以下儿童接受了移植。其中,65例至少发生过一次严重感染,从细菌性脑膜炎到病毒性肺炎不等。在这些婴儿中,19例感染了巨细胞病毒,绝大多数在移植后的头2至3个月出现症状。8例婴儿患有卡氏肺孢子虫肺炎并得到成功治疗。巨细胞病毒感染风险在移植后的前4至8周以及接受了来自血清学阳性供体器官的血清学阴性受者中最高。目前,我们降低活动性疾病可能性的方案包括移植后立即及在接受积极免疫抑制治疗的排斥反应期间使用静脉注射免疫球蛋白,以及在移植后的前3个月使用口服阿昔洛韦。如果发生活动性疾病,则开始使用更昔洛韦。(摘要截选至250词)